DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...

The FDA cleared the investigational new drug (IND) application for EVM14. EVM14 is an off-the-shelf tumor-associated antigen ...

Equities researchers at StockNews.com started coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Get Free Report) in a research report issued on Sunday. The firm set a “hold” rating on the ...

Among other functions, the NK cells (natural killers, a type of lymphocyte forming part of the immune system) have the capacity to detect and eliminate cancer cells. But in some cases they cannot ...

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...

Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...

Artiva Biotherapeutics, Inc.’s ARTV share price has dipped by 12.25%, which has investors questioning if this is right time ...

A team of researchers from the Hospital del Mar Research Institute, the Universitat Autònoma de Barcelona and the Pompeu Fabra University has developed a new tool that allows modifying these NK cells ...

A team of researchers from the Hospital del Mar Research Institute, the Universitat Autònoma de Barcelona and the Pompeu ...

it has several limitations that may be overcome instead through bispecific T-cell-engaging antibodies, according to a speaker. Chimeric antigen receptor T-cell therapy improves not only lupus ...

From the antibodies sequences collected in our database, we computed a score to evaluate the humanness of the VH and VL fragments. As can be seen in Figure 5, our humanness score discriminates well ...

This study shows that RNA decay rather than the presence of premature termination codons triggers a TA-like response.